Results 21 to 30 of about 6,414,902 (294)

Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. [PDF]

, 2010
The unparalleled collection of clinical data and biomaterials within the EHDN's REGISTRY can expedite the search for disease modifiers (genetic and environmental) of age at onset and disease progression that could be harnessed for the development of ...
Handley, Olivia J, Landwehrmeyer, G Bernhard, Aileen K Ho, Bisson, Jonathan Ian, Schwenke C, David Craufurd, Dunnett, Stephen B., Handley, Olivia, Investigators of the European Huntington's Disease Network, The, DI MARIA, EMILIO, Craufurd D, Dunnett, SB, Carsten Schwenke, the investigators of the European Huntington's Disease Network, Craufurd, David, Edward Wild, Landwehrmeyer, GB, Busse, Monica, Rosser, Anne Elizabeth, Olivia J Handley, Romano Silvia., Tabrizi SJ, Ho, Aileen K., Wild, E, Landwehrmeyer GB, Craufurd, D, Tabrizi, SJ, Tabrizi, Sarah J., Handley, OJ, Rickards, Hugh, Dunnett, Stephen, Ho, Aileen K, Orth, Michael, Ho, AK, Wild, Edward, Stephen B. Dunnett, Sarah J Tabrizi, Wild, EJ, Landwehrmeyer, G. Bernhard, Naji, Jenny, Landwehrmeyer, G. Bernhard, Wild E, Investigators of the European Huntington's Disease Network, Handley, Olivia J., Orth, M, Ellison-Rose, Lynda, Tabrizi, Sarah J, Price, Kathleen, Ho AK, ABBRUZZESE, GIOVANNI, Schwenke, C, Ho, A, Orth M, Handley OJ, Schwenke, Carsten, Dunnett SB, Dunnett, Stephen B, Michael Orth, G. Bernhard Landwehrmeyer   +59 more
core   +1 more source

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Haematologica, 2012
Background In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B ...
Hongtao Liu, Jeffrey L. Johnson, Greg Koval, Greg Malnassy, Dorie Sher, Lloyd E. Damon, Eric D. Hsi, Donna Marie Bucci, Charles A. Linker, Bruce D. Cheson, Wendy Stock   +10 more
doaj   +1 more source

Optimization of the indications for allogeneic stem cell transplantation in Acute Myeloid Leukemia based on interactive diagnostic strategies [PDF]

, 2011
The indications for allogeneic stem cell transplantation (SCT) in Acute Myeloid Leukemia (AML) represent a real challenge due to the clinical and genetic heterogeneity of the disorder.
Hartwig, Maite, Zander, Axel R., Haferlach, Torsten, Fehse, Boris, Bacher, Ulrike, Kröger, Nicolaus   +5 more
core   +1 more source

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

Haematologica, 2019
Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies ...
Brian Ball, Eytan M. Stein
doaj   +1 more source

Liquid biopsies and minimal residual disease in lymphoid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and ...
Maroun Bou Zerdan, Joseph Kassab, Ludovic Saba, Elio Haroun, Morgan Bou Zerdan, Sabine Allam, Lewis Nasr, Walid Macaron, Mahinbanu Mammadli, Sarah Abou Moussa, Chakra P. Chaulagain   +10 more
doaj   +1 more source

FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia [PDF]

, 2004
Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the ...
Kern, Wolfgang, Schnittger, Susanne, Haferlach, Torsten, Hiddemann, Wolfgang, Schoch, Claudia   +4 more
core   +1 more source

Assessment of minimal residual disease in standard-risk AML [PDF]

, 2016
Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission.
Griffiths, M, Simpson, MA, Ivey, A, Gale, RE, Russell, N, Farah, H, Wall, K, Akiki, S, Hills, RK, Gilkes, A, McCaughan, F, Freeman, SD, Burnett, AK, Patel, Y, Grech, A, Grimwade, D, Solomon, E, Vyas, P, Mason, J, Jovanovic, JV, Bhudia, N, Linch, DC   +21 more
core   +7 more sources

Liquid biopsies and minimal residual disease in myeloid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies.
Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, Chakra P. Chaulagain   +9 more
doaj   +1 more source

Minimal residual disease in cancer therapy - Small things make all the difference [PDF]

, 2015
Minimal residual disease (MRD) is a major hurdle in the eradication of malignant tumors. Despite the high sensitivity of various cancers to treatment, some residual cancer cells persist and lead to tumor recurrence and treatment failure.
Blatter, Sohvi, Rottenberg, Sven
core   +1 more source

Minimal Residual Disease in Myeloma: Are We There Yet? [PDF]

, 2012
Measurement of minimal residual disease is routine in diseases such as chronic myelogenous leukemia, precursor B cell acute lymphoblastic leukemia, and acute promyelocytic leukemia because it provides important prognostic information.
Kassim, Adetola, Kim, Annette S., Jagasia, Madan H., Savani, Bipin N., Hart, Andrew J., Mosse, Claudio A.   +5 more
core   +1 more source